Acquired hemophilia is a rare bleeding disorder in which your immune system mistakenly produces antibodies that attack one of your body’s essential clotting proteins. Unlike the inherited form of hemophilia that people are born with, acquired hemophilia develops suddenly, often later in life, in someone with no prior history of bleeding problems. It affects roughly 1.5 people per million each year, and about 80% of patients are older than 65.
How It Differs From Inherited Hemophilia
Congenital (inherited) hemophilia results from a genetic mutation that leaves a person unable to produce enough clotting factor from birth. Acquired hemophilia has nothing to do with genetics. It occurs when the immune system begins making autoantibodies, proteins that latch onto clotting factor VIII and neutralize it. Factor VIII is a critical link in the chain of events that forms a blood clot, so when it stops working, uncontrolled bleeding follows.
In healthy people, a small number of harmless, low-level antibodies against factor VIII can actually circulate without causing problems. In acquired hemophilia, something triggers a break in immune tolerance, allowing certain immune cells to multiply and drive a much more aggressive antibody response. These antibodies bind to key regions of the factor VIII protein and either block it from functioning or actively break it down.
Who Gets It and Why
The disease overwhelmingly affects older adults. The median age at diagnosis falls between 74 and 78 years, and incidence rises sharply with age, from 0.045 per million per year in children under 16 to 14.7 per million per year in adults over 85. Overall, men and women are affected equally, with one notable exception: women between the ages of 20 and 40 are diagnosed more often than men of the same age, because pregnancy and the postpartum period are known triggers.
In about half of all cases (roughly 52%), no underlying cause is ever identified. These are called idiopathic cases. Among the rest, malignancy accounts for about 12% and autoimmune diseases for another 12%. Postpartum acquired hemophilia typically appears one to four months after delivery. The remaining cases have been linked to medications, infections, and other inflammatory conditions.
Bleeding Patterns
One of the most distinctive features of acquired hemophilia is the type of bleeding it causes. If you’re familiar with inherited hemophilia, you might associate it with bleeding into the joints. That pattern is actually unusual in acquired hemophilia. Instead, the hallmark presentation is extensive bruising (purpura) and bleeding into soft tissues and muscles. In one long-running review of 24 cases at a single treatment center, 23 of the 24 patients presented with purpura or soft tissue bleeding as their first sign.
Beyond skin and muscle bleeding, common sites include the nose, gums, gastrointestinal tract, and urinary tract. Retroperitoneal bleeding, where blood collects in the space behind the abdominal cavity, also occurs and can be dangerous. Prolonged, difficult-to-stop bleeding after surgery or even minor procedures is another red flag. Because the condition is so rare, many patients experience significant bleeding before the correct diagnosis is made.
How It Is Diagnosed
The first clue is often a routine blood test showing a prolonged activated partial thromboplastin time (aPTT), which measures how long it takes a sample of blood to clot. When this result is unexpectedly high in someone with no personal or family history of bleeding disorders, a follow-up test called a mixing study is performed.
In a mixing study, the patient’s blood plasma is combined 1:1 with normal plasma. If the clotting time corrects back to normal, the problem is simply a deficiency in a clotting factor. If the clotting time fails to correct, especially after the mixture is incubated for a period, it means something in the patient’s plasma is actively interfering with clotting. This “inhibitor pattern” is the diagnostic signature of acquired hemophilia. From there, factor VIII levels are measured directly and found to be low, and the strength of the inhibitor is quantified using a specialized test. Inhibitor strength is reported in Bethesda units (BU): results of 5.0 BU or lower are classified as low titer, while anything above 5.0 BU is high titer. The titer level influences treatment decisions.
Controlling the Bleeding
Treatment has two parallel goals: stop any active bleeding and eliminate the antibodies causing the problem. For acute bleeding episodes, standard factor VIII replacement (the treatment used in inherited hemophilia) often doesn’t work well because the inhibitor antibodies simply neutralize any factor VIII that’s infused. Instead, doctors use “bypassing agents,” medications that activate the clotting cascade through an alternate route, sidestepping the blocked factor VIII step entirely. These agents can be effective at controlling hemorrhage even when factor VIII is completely knocked out.
The choice of bypassing agent and the urgency of treatment depend on the location and severity of bleeding. Mild skin bruising may not require hemostatic treatment at all, while muscle bleeding, surgical bleeding, or retroperitoneal hemorrhage can be life-threatening and needs immediate intervention.
Eliminating the Antibodies
Stopping the bleeding buys time, but the long-term solution is suppressing the immune response that created the antibodies in the first place. This is done with immunosuppressive therapy, typically steroids alone or steroids combined with a second immune-suppressing medication. The goal is to bring the inhibitor titer down to zero and allow factor VIII levels to recover.
When an underlying condition is identified, such as an autoimmune disease or cancer, treating that condition can sometimes help resolve the inhibitor as well. Postpartum cases tend to carry a better prognosis, with some resolving on their own or responding quickly to treatment. In cases where the standard approach fails, additional immunosuppressive strategies are available, though treatment can take weeks to months to fully eradicate the antibodies.
Prognosis and Risks
Acquired hemophilia carries significant risks even with treatment. Mortality varies widely depending on the patient population. Pregnancy-associated cases have a mortality rate around 4%, while in older patients with other health conditions, historical mortality rates have been reported as high as 42%. More recent data suggest that earlier recognition and better treatment options are improving survival, with some studies reporting overall mortality closer to 4%.
Importantly, bleeding itself is not always the leading cause of death. In one population-based study, the most common cause of death was sepsis related to the toxicity of immunosuppressive treatment, not hemorrhage. This reflects the difficult balance clinicians face: the medications needed to eliminate the antibodies can themselves cause serious complications, particularly in elderly patients who may already be frail. Bleeding and cancer-related deaths accounted for smaller fractions of overall mortality in the same study.
For patients whose inhibitors are successfully eradicated, the outlook is considerably better, though relapses can occur. Ongoing monitoring of factor VIII levels and inhibitor titers after remission helps catch any recurrence early.